Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Glargine 3.0 nmol/kg, SC, as a single dose

Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.

Placebo to glargine, SC, as a single dose

Placebo to MK-1092, SC, as a single dose

20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.

Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.